 Tumor Microenvironment
"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in UAMS Profiles by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 0 | 2 | 2 | | 2024 | 4 | 8 | 12 | | 2023 | 0 | 9 | 9 | | 2022 | 2 | 7 | 9 | | 2021 | 2 | 5 | 7 | | 2020 | 0 | 4 | 4 | | 2019 | 1 | 5 | 6 | | 2018 | 0 | 4 | 4 | | 2017 | 0 | 3 | 3 | | 2016 | 2 | 3 | 5 | | 2015 | 0 | 2 | 2 | | 2014 | 1 | 1 | 2 | | 2013 | 1 | 0 | 1 | | 2012 | 2 | 2 | 4 | | 2011 | 1 | 1 | 2 | | 2010 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles over the past ten years.
-
Liu T, Sun T, Chen X, Wu J, Sun X, Liu X, Yan H, Fu Q, Fan Z, Wang X, Cheng P, Cheng W, Wu A. Targeting ARPC1B Overcomes Immune Checkpoint Inhibitor Resistance in Glioblastoma by Reversing Protumorigenic Macrophage Polarization. Cancer Res. 2025 Apr 03; 85(7):1236-1252.
-
Dai L, Choudhary A, Fan J, Huang L, Lin Z, Qin Z. Identification of RP-54745, an IL-1 Inhibitor Displaying Anticancer Activities for KSHV-Related Primary Effusion Lymphoma. J Med Virol. 2025 Feb; 97(2):e70200.
-
Kaur J, Adhikari M, Sabol HM, Anloague A, Khan S, Kurihara N, Diaz-delCastillo M, Andreasen CM, Barnes CL, Stambough JB, Palmieri M, Reyes-Castro O, Zarrer J, Taipaleenm?ki H, Ambrogini E, Almeida M, O'Brien CA, Nookaew I, Delgado-Calle J. Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis. Cancer Res. 2024 12 02; 84(23):3936-3952.
-
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024 11 06; 14(1):194.
-
Strand SH, Houlahan KE, Branch V, Lynch T, Rivero-Guiti?rrez B, Harmon B, Couch F, Gallagher K, Kilgore M, Wei S, DeMichele A, King T, McAuliffe P, Curtis C, Owzar K, Marks JR, Colditz GA, Hwang ES, West RB. Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome. Breast Cancer Res. 2024 Sep 02; 26(1):127.
-
Maraqah HH, Aboubechara JP, Abu-Asab MS, Lee HS, Aboud O. Excessive lipid production shapes glioma tumor microenvironment. Ultrastruct Pathol. 2024 Sep 02; 48(5):367-377.
-
Sabol HM, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S, Choudhury SR, Schinke C, Palmieri M, Barnes CL, Ambrogini E, Nookaew I, Delgado-Calle J. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024 08 01; 109(8):2606-2618.
-
Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Pe?a L, Leiton CV, Hasan M, Babu S, Fassler D, Oentoro J, Bai JK, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos LF, Shroyer KR. Keratin 17 modulates the immune topography of pancreatic cancer. J Transl Med. 2024 05 10; 22(1):443.
-
Schmit SL, Tsai YY, Bonner JD, Sanz-Pamplona R, Joshi AD, Ugai T, Lindsey SS, Melas M, McDonnell KJ, Idos GE, Walker CP, Qu C, Kast WM, Da Silva DM, Glickman JN, Chan AT, Giannakis M, Nowak JA, Rennert HS, Robins HS, Ogino S, Greenson JK, Moreno V, Rennert G, Gruber SB. Germline genetic regulation of the colorectal tumor immune microenvironment. BMC Genomics. 2024 Apr 25; 25(1):409.
-
Taniguchi H, Chavan SS, Chow A, Chan JM, Mukae H, Rudin CM, Sen T. Role of CD38 in anti-tumor immunity of small cell lung cancer. Front Immunol. 2024; 15:1348982.
-
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024 Mar 04; 221(3).
-
Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT, Moaven O. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front Immunol. 2024; 15:1287459.
-
Yu T, Xu-Monette ZY, Lagoo A, Shuai W, Wang B, Neff J, Carrillo LF, Carlsen ED, Pina-Oviedo S, Young KH. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma. Front Immunol. 2024; 15:1335689.
-
Shin IJ, Tangrea M, Emmert-Buck M, Johann DJ. A Microdissection Protocol for Proteogenomic Analysis of Histological Sections to Advance Drug Development. Methods Mol Biol. 2024; 2823:55-75.
-
Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023 Dec; 4(12):1660-1674.
-
Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI, Dutta N, Necela BM, Cannon MJ, Block MS, Knutson KL. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2023 11; 11(11).
-
Ledermann JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, Gonz?lez-Mart?n A, Oaknin A, Ottevanger PB, Rudaitis V, Kobie J, Nebozhyn M, Edmondson M, Sun Y, Cristescu R, Jelinic P, Keefe SM, Matulonis UA. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100. Gynecol Oncol. 2023 11; 178:119-129.
-
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214.
-
John L, Poos AM, Brobeil A, Schinke C, Huhn S, Prokoph N, Lutz R, Wagner B, Zangari M, Tirier SM, Mallm JP, Schumacher S, Vonficht D, Sol?-Boldo L, Quick S, Steiger S, Przybilla MJ, Bauer K, Baumann A, Hemmer S, Rehnitz C, L?ckerath C, Sachpekidis C, Mechtersheimer G, Haberkorn U, Dimitrakopoulou-Strauss A, Reichert P, Barlogie B, M?ller-Tidow C, Goldschmidt H, Hillengass J, Rasche L, Haas SF, van Rhee F, Rippe K, Raab MS, Sauer S, Weinhold N. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nat Commun. 2023 08 17; 14(1):5011.
-
Mendez Valdez MJ, Kim E, Bhatia S, Saad AG, Sidani C, Daggubati L, Chandar J, Seetharam D, Desgraves J, Ingle S, Luther E, Ivan M, Komotar R, Shah AH. Outcomes of HSV-1 encephalitis infection in glioblastoma: An integrated systematic analysis. Microb Pathog. 2023 Aug; 181:106211.
-
Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Curr Oncol Rep. 2023 05; 25(5):479-489.
-
Guzman G, Pellot K, Reed MR, Rodriguez A. CAR T-cells to treat brain tumors. Brain Res Bull. 2023 05; 196:76-98.
-
Yan MM, Li ZX, Chen C, Zhang W, Zhou DB. [Study on the Regulation of Chidamide on CD8+T Cells in T-cell Acute Lymphoblastic Leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb; 31(1):71-75.
-
Jules A, Means D, Troncoso JR, Fernandes A, Dadgar S, Siegel ER, Rajaram N. Diffuse Reflectance Spectroscopy of Changes in Tumor Microenvironment in Response to Different Doses of Radiation. Radiat Res. 2022 12 01; 198(6):545-552.
-
Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022 11 22; 6(22):5873-5883.
-
Thakur CK, Neupane R, Karthikeyan C, Ashby CR, Babu RJ, Boddu SHS, Tiwari AK, Moorthy NSHN. Lysinated Multiwalled Carbon Nanotubes with Carbohydrate Ligands as an Effective Nanocarrier for Targeted Doxorubicin Delivery to Breast Cancer Cells. Molecules. 2022 Nov 02; 27(21).
-
Ledezma DK, Balakrishnan PB, Shukla A, Medina JA, Chen J, Oakley E, Bollard CM, Shafirstein G, Miscuglio M, Fernandes R. Interstitial Photothermal Therapy Generates Durable Treatment Responses in Neuroblastoma. Adv Healthc Mater. 2022 10; 11(20):e2201084.
-
Hussain M, Khan F, Al Hadidi S. The use of bone-modifying agents in multiple myeloma. Blood Rev. 2023 01; 57:100999.
-
Urbaniak A, Reed MR, Heflin B, Gaydos J, Pi?a-Oviedo S, Jedrzejczyk M, Klejborowska G, Stepczynska N, Chambers TC, Tackett AJ, Rodriguez A, Huczynski A, Eoff RL, MacNicol AM. Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer. Biomed Pharmacother. 2022 Sep; 153:113440.
-
Blad? J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosi?ol L, Usmani SZ, Zamagni E, Richardson P. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022 03 21; 12(3):45.
-
Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. Eur J Cancer. 2022 04; 165:81-96.
-
Acharya B, Miah S, Frett B. Targeting TGF-?: triumphs and challenges. Future Med Chem. 2022 04; 14(7):455-458.
-
Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 11; 40(46):6395-6405.
-
Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T, Wilnit A, Mokhtari Z, Tabares P, B?ckle D, Rasche L, Martin Kort?m K, Lutz MB, Einsele H, Brandl A, Beilhack A. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia. 2022 03; 36(3):790-800.
-
van de Donk NWCJ, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021 07; 2(4):302-318.
-
Zhang M, Acklin S, Gillenwater J, Du W, Patra M, Yu H, Xu B, Yu J, Xia F. SIRT2 promotes murine melanoma progression through natural killer cell inhibition. Sci Rep. 2021 06 21; 11(1):12988.
-
Von Suskil M, Sultana KN, Elbezanti WO, Al-Odat OS, Chitren R, Tiwari AK, Challagundla KB, Srivastava SK, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Bruton's Tyrosine Kinase Targeting in Multiple Myeloma. Int J Mol Sci. 2021 May 27; 22(11).
-
Mehdi SJ, Moerman-Herzog A, Wong HK. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma. BMC Cancer. 2021 May 03; 21(1):492.
-
Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mul? J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 04; 204(1):96-106.
-
Mulcrone PL, Edwards SKE, Petrusca DN, Haneline LS, Delgado-Calle J, Roodman GD. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Sci Rep. 2020 10 14; 10(1):17319.
-
Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, Washam CL, Choudhury SR, Hyun Ahn J, Uryu H, Williams JB, Krager KJ, Chiang TC, Mackintosh SG, Edmondson RD, Aykin-Burns N, Gajewski TF, Wang GG, Tackett AJ. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719.
-
Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020 10; 17(10):555-570.
-
Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplant. 2021 01; 56(1):9-19.
-
Schwede M, Waldron L, Mok SC, Wei W, Basunia A, Merritt MA, Mitsiades CS, Parmigiani G, Harrington DP, Quackenbush J, Birrer MJ, Culhane AC. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):509-519.
-
Darrigues E, Nima ZA, Griffin RJ, Anderson JM, Biris AS, Rodriguez A. 3D cultures for modeling nanomaterial-based photothermal therapy. Nanoscale Horiz. 2020 03 01; 5(3):400-430.
-
Post GR, Yuan Y, Holthoff ER, Quick CM, Post SR. Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment. PLoS One. 2019; 14(11):e0224621.
-
Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, Xu W, Wu C, Li J, Zhan F, Wu Y, Yan H. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica. 2020 06; 105(6):1630-1640.
-
Song CW, Griffin RJ, Lee YJ, Cho H, Seo J, Park I, Kim HK, Kim DH, Kim MS, Dusenbery KE, Cho LC. Reoxygenation and Repopulation of Tumor Cells after Ablative Hypofractionated Radiotherapy (SBRT and SRS) in Murine Tumors. Radiat Res. 2019 08; 192(2):159-168.
-
Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res. 2019 03 15; 79(6):1113-1123.
-
van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018; 9:2134.
-
Jamshidi-Parsian A, Griffin RJ, Kore RA, Todorova VK, Makhoul I. Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma. Exp Cell Res. 2018 11 01; 372(1):16-24.
-
DelNero P, Hopkins BD, Cantley LC, Fischbach C. Cancer metabolism gets physical. Sci Transl Med. 2018 05 23; 10(442).
-
Herfs M, Roncarati P, Koopmansch B, Peulen O, Bruyere D, Lebeau A, Hendrick E, Hubert P, Poncin A, Penny W, Piazzon N, Monnien F, Guenat D, Mougin C, Pr?tet JL, Vuitton L, Segers K, Lambert F, Bours V, de Leval L, Valmary-Degano S, Quick CM, Crum CP, Delvenne P. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. Br J Cancer. 2018 05; 118(10):1302-1312.
-
Rahal OM, Wolfe AR, Mandal PK, Larson R, Tin S, Jimenez C, Zhang D, Horton J, Reuben JM, McMurray JS, Woodward WA. Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2018 03 15; 100(4):1034-1043.
-
Spurgeon ME, den Boon JA, Horswill M, Barthakur S, Forouzan O, Rader JS, Beebe DJ, Roopra A, Ahlquist P, Lambert PF. Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen. Proc Natl Acad Sci U S A. 2017 10 24; 114(43):E9076-E9085.
-
Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF. Neutral tumor evolution in myeloma is associated with poor prognosis. Blood. 2017 10 05; 130(14):1639-1643.
-
Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. 2016 Dec 13; 7(50):82482-82492.
-
Zhang W, Bai JF, Zuo MX, Cao XX, Chen M, Zhang Y, Han X, Zhong DR, Zhou DB. PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Med. 2016 11; 5(11):3077-3084.
-
Dai L, Bai L, Lin Z, Qiao J, Yang L, Flemington EK, Zabaleta J, Qin Z. Transcriptomic analysis of KSHV-infected primary oral fibroblasts: The role of interferon-induced genes in the latency of oncogenic virus. Oncotarget. 2016 Jul 26; 7(30):47052-47060.
-
D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med. 2016 05 02; 213(5):827-40.
-
Jolly LA, Novitskiy S, Owens P, Massoll N, Cheng N, Fang W, Moses HL, Franco AT. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss. Cancer Res. 2016 04 01; 76(7):1804-13.
-
Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer. 2015 Nov 06; 15:864.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|